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Abstract
Background: Dysplasia assessment of Barrett’s esophagus biopsies is associated with low observer agreement; guidelines
advise expert review. We have developed a web-based review panel for dysplastic Barrett’s esophagus biopsies.
Objective: The purpose of this study was to test if 10 gastrointestinal pathologists working at Dutch Barrett’s esophagus
expert centres met pre-set benchmark scores for quality criteria.
Methods: Ten gastrointestinal pathologists twice assessed 60 digitalized Barrett’s esophagus cases, enriched for dysplasia;
then randomised (7520 assessments). We tested predefined benchmark quality criteria: (a) percentage of ‘indefinite for
dysplasia’ diagnoses, benchmark score 14% for all cases, 16% for dysplastic subset, (b) intra-observer agreement;
benchmark score 0.66/0.39, (c) percentage agreement with ‘gold standard diagnosis’; benchmark score 82%/73%,
(d) proportion of cases with high-grade dysplasia underdiagnosed as non-dysplastic Barrett’s esophagus; benchmark score
1/78 (1.28%) assessments for dysplastic subset.
Results: Gastrointestinal pathologists had seven years’ Barrett’s esophagus-experience, handling seven Barrett’s
esophagus-cases weekly. Three met stringent benchmark scores; all cases and dysplastic subset, three met extended
benchmark scores. Four pathologists lacked one quality criterion to meet benchmark scores.
Conclusion: Predefined benchmark scores for expert assessment of Barrett’s esophagus dysplasia biopsies are stringent and
met by some gastrointestinal pathologists. The majority of assessors however, only showed limited deviation from bench-
mark scores. We expect further training with group discussions will lead to adherence of all participating gastrointestinal
pathologists to quality criteria, and therefore eligible to join the review panel.
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Key summary
. Barrett’s esophagus (BE) with dysplasia is a proven risk factor for the development of esophageal
adenocarcinoma.
. Observer agreement for the diagnosis of low-grade dysplasia in BE is low, prompting guidelines to advise
expert review.
. This study shows that expert review can be objectiﬁed by using pre-deﬁned benchmark quality criteria for
histological assessment of BE biopsies.
. This study establishes that expertise according to benchmark criteria can be acquired and maintained
using digital pathology training.
. This study implies that constant output quality within a digital pathology review panel can be maintained
when expanding the number of pathologists.
Introduction
In Barrett’s esophagus (BE), the normal stratiﬁed squa-
mous epithelium of the distal esophagus has been
replaced by columnar epithelium with or without
goblet cells. Patients with BE have a risk of developing
esophageal adenocarcinoma (EAC) and malignant
transformation follows the metaplasia – dysplasia –
carcinoma sequence.1 BE patients therefore undergo
endoscopic surveillance. Low-grade dysplasia (LGD)
in biopsies obtained during endoscopic surveillance is
an accepted risk factor for progression, but diagnosis
can be diﬃcult and interobserver agreement is low.2,3
Therefore, guidelines advise review of all dysplastic
cases by a second, preferably expert, pathologist.4–11
In The Netherlands we have initiated a national digi-
tal review panel for dysplastic BE, consisting of ﬁve
core pathologists considered ‘experts’ in the ﬁeld of
BE. These ﬁve expert BE pathologists have been dedi-
cated to the ﬁeld of BE for a minimum of 10 years, have
a minimum caseload of ﬁve BE cases per week of which
25% is dysplastic, have participated in multiple train-
ing programs (www.best-academia.eu), and have co-
authored on >5 peer reviewed publications in this
ﬁeld. Moreover, it is the only BE expert pathologist
group of individuals worldwide that have validated
their BE diagnostic assessments in prospective clinical
studies.12–15 To optimize the throughput time of the
Dutch digital review panel, to divide the workload
and to gain nationwide coverage, we aim to expand
the panel with 10 gastrointestinal (GI) pathologists
from the eight BE expert centres in The Netherlands.
To maintain panel diagnostic quality we need to con-
ﬁrm that these pathologists’ assessments correspond
with the assessment standards of the current ﬁve core
pathologists. In an earlier study, we deﬁned benchmark
quality criteria, based on the assessment of the core
pathologists of a study set of 60 whole-endoscopy
cases.16 The aim of this study was to evaluate if the
assessment scores of 10 dedicated GI pathologists,
reviewing the same study set of 60 whole-endoscopy
cases, fall within the predeﬁned range for these bench-
mark quality criteria.
Materials and methods
Case selection and slide scanning
For 60 patients who had had an endoscopy for BE
surveillance, we selected all formalin ﬁxed, paraﬃn
embedded tissue blocks and/or slides of the biopsies
obtained during the endoscopy. The case set consisted
of 39 cases with an original diagnosis of LGD (n¼ 20) or
high-grade dysplasia (HGD; n¼ 19) that had been sent
to our centre for consultation, between 2012 and 2014.
These 39 dysplastic cases were supplemented with
21 consecutive non-dysplastic BE (NDBE) cases from
a community hospital in the Amsterdam region.
The ﬁve core expert BE pathologists had assessed
this case set twice individually at an earlier stage fol-
lowed by consensus meetings to create a gold standard
diagnosis for all cases.16 Their scores were used to
create benchmark values for the quality criteria.
Assessors
The assessors were 10 dedicated GI pathologists work-
ing in the eight BE expert centres in The Netherlands.
In accordance with Dutch guidelines, work-up
and treatment of dysplastic BE is centralized in
these specialized centers. All pathologists had been
dedicated to the ﬁeld of BE for a median of seven
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years (range 5–30 years) and had a median case load of
seven BE cases per week (range 5–17), of which 25%
were dysplastic. All were actively practicing patholo-
gists, considered experts by their peers, and had already
participated in a joint training programme consisting of
evaluating and discussing 60 single-slide BE cases (35
dysplastic), of which the results were published
separately.17
Histological assessment of samples
For the current study, the pathologists independently
assessed all 60 cases twice in random order, with a
wash-out time of at least one month, scoring them
according to the modiﬁed Vienna criteria for GI neo-
plasms.2,18 The p53 immunohistochemistry (IHC) was
used as a diagnostic adjunct and scored according to
the p53 decision rule developed earlier.17 The patholo-
gists individually logged onto the virtual slide system to
assess the cases and record the highest diagnostic grade
per case. After two assessment rounds, all cases that did
not have a majority diagnosis were discussed in a face-
to-face group discussion with all participants, for edu-
cational purposes.
Definition of benchmark values for quality criteria
For each of the four quality criteria, a benchmark range
had been calculated based on the scores of the ﬁve core
pathologists in the aforementioned earlier study (see
Table 1).16 The ﬂow chart of the study can be seen in
Figure 1.
Outcome measurements
Per pathologist, we established whether the scores met
all benchmark quality criteria, for the complete case set
as well as for the dysplastic subset (Figure 2). The dif-
ferent outcome measurements were calculated as per
our previous study.16 Figure 2 illustrates the spectrum
of diagnostic agreement, over- and underdiagnoses.
Results
Baseline characteristics of samples in case set
The median age of patients at diagnosis was 66 years
(interquartile range (IQR) 13) and 73% were
male. Cases contained a total of 151 sets of quadrant
biopsies with a median of ﬁve slides (IQR 3–9), from a
median of two levels (IQR 1–4) with four biopsies per
level (IQR 3–4.5), with a total of 376 slides to be
assessed.
Performance of 10 pathologists for the complete
case series (n¼ 60)
The pathologists generated a total of 1200 case diag-
noses over 7520 assessed slides. For the percentage of
indeﬁnite for dysplasia (IND) cases, eight out of
10 pathologists met the benchmark value (see
Figure 3(a)). For the intra-observer agreement, nine
out of 10 pathologists fell within the benchmark value
(see Figure 3(b)). For the percentage agreement with
the consensus gold standard diagnosis, ﬁve out of
10 pathologists fell within the benchmark value (see
Figure 3(c)). For the consensus HGD cases misdiag-
nosed as NDBE, eight pathologists fell within the
benchmark value (see Figure 3(d)). In Supplementary
Material Table 1, these results are visualised in cross
tables per pathologist compared to the consensus gold
standard diagnosis. For the complete case set, ﬁve out
of 10 pathologists met the benchmark values for all
four criteria.
Table 1. Values for benchmark quality criteria based on 95% prediction interval (PI) of five core pathologists.16
Quality criterion
95% PI core
pathologists all
cases (n¼ 60) Benchmark value
95% PI core
pathologists
dysplastic
cases (n¼ 39) Benchmark value
Percentage of IND* cases (%) 3–14% 14% 2–16% 16%
Intra-observer agreement in
3 categories (K)
0.66–1.02 0.66 0.39–0.73 0.39
Agreement with consensus
gold standard diagnosis (%)
82–98% 82% 73–104% 73%
Consensus HGDy cases
misdiagnosed as NDBEz
(%; fraction)
0.8% (1/120
assessments)
0.8% (1/120
assessments)
1.3% (1/78
assessments)
1.3% (1/78
assessments)
*IND: indefinite for dysplasia; yHGD: high-grade dysplasia, zNDBE: non-dysplastic Barrett’s esophagus
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Performance of 10 pathologists for subset of
dysplastic cases (n¼ 39)
For the percentage of IND cases, all pathologists fell
within the benchmark value (see Figure 3(e)). For the
intra-observer agreement, six out of 10 pathologists fell
within the benchmark value (see Figure 3(f)). For the
percentage agreement with the consensus gold standard
diagnosis, nine out of 10 pathologists fell within the
benchmark value (see Figure 3(g)). For the consensus
HGD cases misdiagnosed as NDBE, eight out of 10
pathologists fell within the benchmark value (see
Figure 3(h)). In Supplementary Material Table 2 these
results are visualised in cross tables per pathologist
compared to the consensus gold standard diagnosis.
For the dysplastic subset, six out of 10 pathologists
met the benchmark values for all four criteria.
Performance of pathologists relative to
benchmark scores
Overall, three out of 10 pathologists met all benchmark
values for the complete case set as well as for the dys-
plastic subset. When we extended our benchmark qual-
ity criteria by using a wider range, the 99% prediction
interval (PI) scores of the ﬁve core pathologists, an
extra three pathologists met the benchmark range
(results not shown). Four pathologists did not meet
the 99% PI benchmark range on one quality criterion,
namely the intra-observer agreement of the dysplastic
subset, or the percentage of HGD gold standard cases
misdiagnosed as NDBE.
Discussion
The aim of this study was to test if 10 GI pathologists
working at the eight BE expert centres in The
Netherlands met pre-set benchmark scores of pre-de-
ﬁned quality criteria for evaluating BE biopsies (see
Table 1), by assessing a case set of 60 BE cases consist-
ing of 376 slides. To our knowledge, this is the ﬁrst time
5 core experts
10 dedicated
pathologists 1. % IND
* cases
2. intra-observer agreement 
3. % agreement with gold standard
4. % consensus HGD† cases
misdiagnosed as NDBE‡
1. Consensus gold standard diagnosis
2. Benchmark values for quality criteria
Case set
(n = 60 cases)
Complete set
(n = 60)
Dysplastic subset
(n = 39)
Figure 1. Flowchart of study set-up.
*Indefinite for dysplasia; yhigh-grade dysplasia; znon-dysplastic Barrett’s esophagus.
NDBE
NDBE
IND
IND
LGD
LGD
HGD
HGD
*
Consensus gold standard diagnosis
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ist
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Figure 2. Example of 4 4 cross table of pathologist against
consensus gold standard diagnosis, showing the position of
agreement, overdiagnosis and underdiagnosis. IND: indefinite
for dysplasia; LGD: low-grade dysplasia.
*Significant misdiagnoses: number of consensus high-grade dys-
plasia (HGD) cases misdiagnosed as non-dysplastic Barrett’s
oesophagus (NDBE).
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Figure 3. (a)–(d) Performance of 10 gastrointestinal pathologists relative to benchmark criteria, for the complete case set. (e)–(h)
Performance of 10 gastrointestinal pathologists relative to benchmark criteria, for the dysplastic subset.
Vertical line; benchmark value; horizontal line; 95% prediction interval. HGD: high-grade dysplasia; IND: indefinite for dysplasia;
NDBE: non-dysplastic Barrett’s oesophagus.
*IND: indefinite for dysplasia; yHGD: high-grade dysplasia, zNDBE: non-dysplastic Barrett’s esophagus, §PI: prediction interval.
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that histopathological expertise has been quantiﬁed in
the assessment of dysplastic BE biopsies. These criteria
and benchmark values were established in an earlier
study by using the assessments of ﬁve core expert BE
pathologists as reference. These ﬁve pathologists are
considered experts in BE diagnostics according to pre-
viously deﬁned criteria: they have been dedicated to the
ﬁeld of BE for at least 15 years (range 15–45 years);
have a median case load of seven cases per week (range
5–15), of which 25% are dysplastic; they participated
in the Dutch Barrett advisory committee for 5–13
years12,19,20 and have co-authored more than 10 peer-
reviewed publications in this ﬁeld.12–17,19,21–30 To create
a consensus gold standard diagnosis for this case set,
these ﬁve core pathologists assessed the same dataset as
used in this study, twice independently, followed by
group discussions.
In the current study, the boundaries of the 95% PI
and 99% PI of their individual scores were used as
benchmark ranges to assess the performance of 10 dedi-
cated GI pathologists working at the eight Dutch BE
expert centers. These 10 pathologists have been dedi-
cated to the ﬁeld of BE with varying levels of experience
(median of seven years (range 5–30), minimum case
load of seven BE biopsies per week (range 5–17) of
which 25% are dysplastic), however they did not
have the intensive collaboration that the ﬁve core
pathologists had. When comparing their assessments
to the benchmark scores, we found that three out of
10 GI pathologists met all pre-set benchmark ranges
for the quality criteria, for the complete case set as
well as for the subset of dysplastic cases. Performance
according to the benchmark range of the dysplastic
subset is of key importance, since this subset is the
main patient population for review requests by the
national digital review panel. Their adherence to
the benchmark ranges implies that these three path-
ologists perform similarly to the ﬁve core members
in their diagnostic assessment. Expanding the digital
revision panel with these three pathologists would
therefore not compromise the current assessment
homogeneity.
The results of our study need to be interpreted with
caution. First of all, we have used intra-observer agree-
ment (weighted kappa) as an indirect measure of expert-
ise, because it underscores the individual reproducibility
of the pathologist. However, calculating a kappa score
can be less reliable when marginal totals are skewed,
leading to a high chance of agreement and therefore a
low kappa score. This is of particular relevance for the
subanalysis of the dysplastic cases (where it is ampliﬁed
by the low numbers in the subanalysis). Taking these
aspects of the kappa calculation into account, we feel
that the intra-observer agreement of the subanalysis is
less reliable as a benchmark score than measuring
diversions from the consensus gold standard diagnoses,
i.e. the percentage agreement per pathologist. The per-
centage agreement of nine out of 10 pathologists falls
within the 95% PI benchmark range for this criterion.
This outcome signiﬁes correct detection of dysplastic
cases (Figure 3(g)). If we did not take the intra-observer
agreement into account, one additional pathologist
meets the predeﬁned benchmark values. Second, the
95% PI benchmark range of percentage of cases ‘indef-
inite for dysplasia’ is inﬂated compared to clinical prac-
tice. This is explained by the fact that our case set was
strongly enriched for diﬃcult dysplastic cases, as
encountered in a review panel setting, and by the fact
that we used a p53 decision rule in the interpretation of
p53 IHC as a diagnostic adjunct.17 Moreover, the cur-
rent study is part of a structured training programme
and after the individual assessments presented here, the
10 GI pathologists participated in face-to-face plenary
group meetings, discussing cases that were discrepant
with the consensus gold standard diagnosis.
Importantly, after completion of this study set, all path-
ologists have assessed a case set of 62 endoscopic resec-
tion cases, and are currently reviewing 40 cases sent to
the national digital review panel. These assessments
were again combined with face-to-face plenary group
meetings, to discuss diﬃcult and discrepant cases. This
will further improve the experience and homogeneity of
panel members. We aim to reevaluate their performance
in the near future, and consequently expect more path-
ologists to meet the benchmark quality criteria
presented here.
This study has some limitations. The benchmark
quality criteria used in this study depend on the distri-
bution of diagnoses in this dataset and the individual
scores of the ﬁve core pathologists. The benchmark
scores only apply to this speciﬁc digital study set and
the number and scores of the core pathologists.
However, because there is no standardized way to
deﬁne expertise in BE diagnostics, we feel that these
benchmark quality criteria are currently the best
choice to quantify expertise when diagnosing BE dys-
plasia in biopsy samples in The Netherlands.
This study is unique because of a number of features.
First, it is part of a structured approach to guarantee
quality and uniformity of histological diagnosis of BE
biopsies in The Netherlands. Over the past ﬁve years,
our group has set up a national digital review panel for
BE after conducting ﬁve preliminary studies.16,17,30
This is the ﬁrst time worldwide that an expert path-
ology review panel has been set up conducting such
quantiﬁable preliminary work in such a meticulous
way. Second, the case set used for this study consisted
of all slides from all biopsy levels of a single endoscopy
(376 slides in total), was fully digitalized and only con-
tained review cases from clinical practice. There were
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two assessment rounds with an adequate wash-out
time. In order to improve homogeneity of the group
the pathologists held a group discussion afterwards to
discuss cases that did not have a majority diagnosis.
This digital case set of dysplastic BE cases will be
made available to allow pathologists in and outside
The Netherlands to evaluate if they meet the aforemen-
tioned benchmark ranges for quality criteria.
Our goal for the future remains to improve the
knowledge of BE-related diagnostic pathology among
GI pathologists in The Netherlands; and to include all
GI pathologists working at the BE expert centers in The
Netherlands in our review panel. For this, we ﬁrst need
to ensure quality and homogeneity of the panel as out-
lined above. Subsequently, we need a prediction model
that allows us to eﬃciently select the number of path-
ologists needed for reviewing cases and to divide the
workload equally among panel members. We aim to
improve and expand training in BE pathology both
nationally as well as internationally by constructing a
freely available, accredited training module incorporat-
ing the information gathered from all study sets and
group discussions thus far.16,17,30 In this way, patholo-
gists with an interest in BE can train themselves and
reﬂect on their performance relative to the benchmark
scores of the training set.
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